Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
1989-10-3
|
| pubmed:abstractText |
The research programme leading to the discovery of clavulanic acid and the olivanic acids (carbapenems) is reviewed. The beta-lactamase inhibitory properties of clavulanic acid and its development as a formulation with amoxycillin (Augmentina) and ticarcillin (Timentin) are described. The chemistry of clavulanic acid as well as the properties of the carbapenem family of antibiotics is outlined as are the other beta-lactamase inhibitors prompted by the development of clavulanic acid.
|
| pubmed:language |
eng
|
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:author | |
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1-21
|
| pubmed:dateRevised |
2005-11-16
|
| pubmed:meshHeading | |
| pubmed:articleTitle |
Clavulanic acid, a novel beta-lactamase inhibitor--a case study in drug discovery and development.
|
| pubmed:affiliation |
Beecham Pharmaceuticals Research Division, Surrey, U.K.
|
| pubmed:publicationType |
Journal Article,
Review
|